Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Vitro Biopharma, Inc. (Name of Issuer) Common (Title of Class of Securities) 928501303 (CUSIP Number) 09/09/22 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) x Rule 13d-1(d) CUSIP No. 928501303 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Jack Zamora, M.D. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC use only 4. Citizenship or place of organization: United States citizen 5. Sole Voting Power 0 6. Shared Voting Power 37,049,318 7. Sole Dispositive Power 37,049,318 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially owned by Each Reporting Person 37,049,318 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 31.4% 12. Type of Reporting Person (See Instructions) IN Item 1 (a) Name of Issuer: Vitro Biopharma, Inc (b) Address of Issuer?s Principal Executive Offices 4621 Technology Drive, Golden, CO 80403 Item 2 (a) Name of Person Filing Jack Zamora, M.D. (b) Address of Principal Business Office or, if none, Residence c/o Vitro Biopharma, 4621 Technology Drive, Golden, CO 80403 (c) Citizenship United States (d) Title of Class of Securities Common (e) CUSIP Number 928501303 Item 3 If this statement is filed pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with ?240.13d-1(b)(1)(ii)(E). (f) An employee benefit plan or endowment fund in accordance with ?240.13d- 1(b)(1)(ii)(F). (g) A parent holding company or control person in accordance with ?240.13d- 1(b)(1)(ii)(G). (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). (j) Group, in accordance with ?240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 37,049,318 (b) Percent of Class: 31.4% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 37,049,318 (iii) Sole power to dispose or to direct the disposition of 37,049,318 (iv) Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certification. Not applicable SIGNATURE After reasonable inquiry and to the best of my Knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 2-14-23 Date /s/ Jack Zamora, M.D. Signature Jack Zamora, M.D. Name